Exact Sciences Corp. on Wednesday announced the launch of the Cancerguard test, a new multi-cancer early detection blood test that is now available as a laboratory-developed test in the United States.
Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited.
With a blood draw, the Cancerguard test can detect signals from cancer types responsible for more than 80% of annual U.S. cancer diagnoses, including some with the highest mortality rates, such as pancreatic, ovarian, liver, esophageal, lung and stomach cancers.
Click here to read the full article.